Comparative Pharmacology
Head-to-head clinical analysis: MIVACRON versus NORCURON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MIVACRON versus NORCURON.
MIVACRON vs NORCURON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Mivacurium is a bis-benzylisoquinoline neuromuscular blocking agent that acts as a competitive antagonist at nicotinic acetylcholine receptors at the neuromuscular junction, leading to muscle paralysis.
Competitive antagonist of nicotinic acetylcholine receptors at the neuromuscular junction, preventing acetylcholine binding and inducing skeletal muscle paralysis.
0.15-0.2 mg/kg IV bolus for intubation; maintenance infusion 9-10 mcg/kg/min
0.08-0.1 mg/kg IV bolus for intubation; maintenance 0.01-0.015 mg/kg IV every 30-60 min as needed or continuous infusion at 0.06-0.12 mg/kg/hr.
None Documented
None Documented
Terminal elimination half-life is approximately 2-3 minutes; clinically, rapid clearance via plasma cholinesterase results in short duration.
Terminal elimination half-life is approximately 1.3-2.2 hours in adults; prolonged in hepatic or renal impairment (up to 3-4 hours in renal failure).
Primarily renal (approximately 80-90% as unchanged drug and metabolites) and biliary (small fraction, <20% as metabolites).
Approximately 40-50% of the dose is excreted unchanged in urine within 24 hours; 20-30% is eliminated in feces as unchanged drug and metabolites; minor biliary excretion.
Category C
Category C
Neuromuscular Blocker
Neuromuscular Blocker